里瓦斯蒂格明:患有勒维体的痴呆症
Kimberly A Madson1, Sherrill Brown1
1Department of Pharmacy Practice, University of Montana, Skaggs School of Pharmacy, Missoula, Montana.
Hospital pharmacy
|May 15, 2024
概括
该资源有助于医疗保健专业人员快速找到和评估非标签药物用途. 它指导临床医生确定未经批准的药物应用在患者护理场景中的合理性.
科学领域:
- 药房实践 在药房实践.
- 药物信息 药物信息
- 临床药理学 临床药理学
背景情况:
- 在临床实践中,非标签药物的使用是常见的.
- 关于未经批准的药物使用的信息可能是碎片化的.
- 医疗保健专业人员需要可靠的资源来获得非标签药物信息.
研究的目的:
- 为非标签药物使用提供面向实践者的资源.
- 为了使临床医生能够识别和评估关于未经批准的药物应用的已发表研究.
- 支持关于非标签药物使用的合理患者护理决策.
主要方法:
- 从出版物"非标签药物事实"中提取信息.
- 文献综述和关于特定非标签药物使用的研究综合.
- 提供参考资料以提供进一步的全面信息.
主要成果:
- 现在可以获得关于非标签药物使用的出版文献指南.
- 临床医生可以有效地识别支持特定未经批准的药物应用的研究.
- 该资源有助于评估患者护理中非标签药物使用的合理性.
结论:
- 标签外药物事实为医疗保健专业人员提供了宝贵的工具.
- 该资源有助于为未经批准的药物使用提供基于证据的决策.
- 获得更好的信息支持更安全,更有效的患者护理.
相关概念视频
Parkinson's Disease: Treatment
263
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
263
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Parkinson's Disease: Overview
533
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
533
Anticholinesterase Agents: Poisoning and Treatment
850
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
850
Alzheimer's Disease: Overview
467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467


